Patents Examined by Anne M. Gussow
-
Patent number: 7847068Abstract: The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.Type: GrantFiled: November 13, 2006Date of Patent: December 7, 2010Assignee: Schering CorporationInventors: Yan Wang, Robert Greenberg, Leonard Presta, Jonathan A. Pachter, Judith Hailey, Peter Brams, Denise Williams, Mohan Srinivasan, Diane Feingersh
-
Patent number: 7829673Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: March 23, 2006Date of Patent: November 9, 2010Assignee: Genmab A/SInventors: Michel De Weers, Yvo Graus, Judith Oprins, Paul Parren, Jan Van De Winkel, Martine Van Vugt
-
Patent number: 7829678Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.Type: GrantFiled: November 7, 2008Date of Patent: November 9, 2010Assignee: Neogenix Oncology, Inc.Inventors: J. Andrew Bristol, Judith A. Kantor
-
Patent number: 7829088Abstract: The present invention is related to a pharmaceutical composition comprising humanized anti-4-1BB antibody (HBBK4) for treating cancer by inducing increase of CD11+CD8+ T cell and IFN-?, and inhibiting proliferation of cancer cells, together with a pharmaceutically acceptable carrier and the use. Accordingly, it can be useful in the prevention or treatment of cancer without adverse response.Type: GrantFiled: May 24, 2006Date of Patent: November 9, 2010Assignee: University of Ulsan Foundation for Industry CooperationInventor: Byoung Se Kwon
-
Patent number: 7829674Abstract: The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.Type: GrantFiled: October 26, 2007Date of Patent: November 9, 2010Assignee: Lpath, Inc.Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams
-
Patent number: 7815907Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: GrantFiled: June 2, 2005Date of Patent: October 19, 2010Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Bruce D Cohen, Jean Beebe, Penelope E Miller, James D Moyer, Jose R Corvalan, Michael Gallo
-
Patent number: 7812133Abstract: The invention provides anti-OX40L antibodies, and compositions comprising and methods of using these antibodies.Type: GrantFiled: December 15, 2006Date of Patent: October 12, 2010Assignee: Genentech, IncInventor: Flavius Martin
-
Patent number: 7790866Abstract: The present invention provides: a novel DNA, a carcinoma-associated gene comprising the DNA, a recombinant protein encoded by the DNA, an antibody binding to the protein, an anti-carcinoma agent comprising the antibody, a low-molecular-weight compound binding to the protein, and a screening system. An example of such a novel DNA is a DNA comprising a nucleotide sequence encoding the following polypeptide (a) or (b): (a) a polypeptide, consisting of an amino acid sequence identical to or substantially identical to the amino acid sequence represented by SEQ ID NO: 2; or (b) a polypeptide, consisting of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 by deletion, substitution, or addition of one or a plurality of amino acids and having biological activity substantially equivalent to the functions of the polypeptide (a).Type: GrantFiled: November 20, 2003Date of Patent: September 7, 2010Assignees: Chugai Seiyaku Kabushiki Kaisha, Kazusa DNA Research InstituteInventors: Osamu Ohara, Takahiro Nagase, Reiko Kikuno, Shin-ichi Funahashi
-
Patent number: 7785903Abstract: The invention provides polypeptides comprising a variant heavy chain variable framework domain (VFR). In some embodiments, the amino acids defining the VFR form a loop of an antigen binding pocket. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR. The polypeptide may optionally comprise one or more complementary determining regions (CDRs) of antibody variable domains. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR and one or more variant CDRs. Libraries of polypeptides that include a plurality of different antibody variable domains generated by creating diversity in a VFR, and optionally, one or more CDRs are provided and may be used as a source for identifying novel antigen binding polypeptides that can be used therapeutically or as reagents. The invention also provides fusion polypeptides, compositions, and methods for generating and using the polypeptides and libraries.Type: GrantFiled: April 8, 2005Date of Patent: August 31, 2010Assignee: Genentech, Inc.Inventors: Christopher J. Bond, Sachdev Sidhu
-
Patent number: 7786266Abstract: The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides methods and pharmaceutical compositions that comprise anti-DSC2 antibody as an active ingredient for damaging DSC2-expressing cells via the effector function of the antibody.Type: GrantFiled: May 11, 2006Date of Patent: August 31, 2010Assignee: Oncotherapy Science, Inc.Inventors: Shuichi Nakatsuru, Takashi Iwamoto, Megumi Yoshikawa
-
Patent number: 7781398Abstract: The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell proliferation, resulting in a broad spectrum of anticancer activity. The invention also relates to pharmaceutical compositions containing a combination of such peptide analogs.Type: GrantFiled: December 21, 2006Date of Patent: August 24, 2010Assignee: Dabur Pharma Ltd.Inventors: Rama Mukherjee, Anand C. Burman, Anu T. Singh, Manu Jaggi, Sudhanand Prasad, Sarjana Dutt
-
Patent number: 7777008Abstract: The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic cells (DC), e.g., monocyte-derived dendritic cells (MDDC). The binding molecules of the invention are characterized by binding to hILT3 with high affinity and downmodulating immune responses in vitro, e.g., downmodulating alloimmune responses; the production of inflammatory cytokines by dendritic cells, e.g., monocyte-derived dendritic cells (MDDC); the upregulation of costimulatory molecules by DC, e.g., MDDC; and/or calcium flux in monocytes. In addition, the binding molecules upregulate the expression of inhibitory receptors on dendritic cells, e.g., immature dendritic cells. Surprisingly, these same binding molecules which downmodulate immune responses in vitro, are immunostimulatory in vivo. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof.Type: GrantFiled: June 19, 2007Date of Patent: August 17, 2010Assignee: Tolerx, Inc.Inventors: Paul Ponath, Michael Rosenzweig, Jose F. Ponte
-
Patent number: 7777018Abstract: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CFR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.Type: GrantFiled: October 29, 2007Date of Patent: August 17, 2010Assignee: Centocor, Inc.Inventors: Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
-
Patent number: 7777019Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.Type: GrantFiled: February 13, 2008Date of Patent: August 17, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Ira Pastan, Giuliana Salvatore, Richard Beers, Robert J. Kreitman
-
Patent number: 7754859Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.Type: GrantFiled: August 3, 2007Date of Patent: July 13, 2010Assignee: AstraZeneca ABInventors: Naomi Laing, Jaspal Singh Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, David Charles Blakey, Sue A. Cartlidge
-
Patent number: 7750125Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene.Type: GrantFiled: August 17, 2007Date of Patent: July 6, 2010Assignee: University of RochesterInventors: Maurice Zauderer, Elizabeth E. Evans
-
Patent number: 7740872Abstract: The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation of the cancer cells, a portion of the cancer cell antigens remain intact. These exposed antigens, or epitopes, foster and promote antibody production. The resulting modified cancer cell particle, or portions of the cancer cell, initiate a positive immunogenic response when administered to an animal or human and help to treat, prevent or delay the onset of cancer. The present invention provides autologous and heterologous vaccine compositions comprising the modified cancer cell with a pharmaceutically acceptable carrier. The present invention provides method of administering these vaccines to treat, prevent or delay the onset of cancer.Type: GrantFiled: March 7, 2008Date of Patent: June 22, 2010Assignee: Eli Lilly and CompanyInventors: Moiz Kitabwalla, Hassibullah Akeefe
-
Patent number: 7728113Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: GrantFiled: August 20, 2007Date of Patent: June 1, 2010Assignees: Amgen Fremont Inc., Warner-Lambert Company LLCInventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimée Kellermann, Joseph Edwin Low, James Leslie Mobley
-
Patent number: 7727526Abstract: The present invention concerns the use of a PTHrP antagonist for preparing a pharmaceutical composition for treating renal cell carcinoma (RCC) in a mammal and in particular in a human subject. Advantageously, the invention is of particular interest for inhibiting or reducing tumour growth and/or metastasis formation in kidney cancer and its metastatic developments, in particular in the lung and the liver.Type: GrantFiled: July 4, 2003Date of Patent: June 1, 2010Assignees: Universite Louis Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM), Hopitaux Universitaires de StrasbourgInventors: Thierry Massfelder, Herve Lang, Eric Schordan, Jean-Jacques Helwig
-
Patent number: 7723485Abstract: Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.Type: GrantFiled: May 7, 2008Date of Patent: May 25, 2010Assignee: Genentech, Inc.Inventors: Jagath R. Junutula, William Mallet